Insulet vs Revvity
Revvity reported revenue of $2.9 billion in fiscal 2025, about the same as Insulet's $2.7 billion in fiscal 2025. Insulet's revenue grew 30.7% in its latest year, and Revvity's grew 3.7%. Insulet had an operating margin of 17.5%, against 12.5% at Revvity. Free cash flow was $378 million at Insulet and $509 million at Revvity. Their fiscal years end in different months (December 31 and December 28), so the periods don't line up exactly.
Side by side
| Insulet | Revvity | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 28, 2025 |
| Revenue | $2.7B | $2.9B |
| Revenue growth | 30.7% | 3.7% |
| Revenue growth a year, last 5 years | 24.5% | −5.5% |
| Gross margin | 71.6% | — |
| Operating margin | 17.5% | 12.5% |
| Net margin | 9.1% | 8.4% |
| Free cash flow | $378M | $509M |
| Free cash flow margin | 13.9% | 17.8% |
| Return on capital | 20.4% | 3.3% |
| Net debt to EBITDA | 0.4x | 3.0x |
| Dividends and buybacks | $60M | $854M |
| Change in diluted share count | −2.7% | −5.1% |
| Last close | $149.26 | $160.39 |
| P/E at the last close | 28.0× | 76.7× |
| Insider trades, last 12 months | bought $2.9 million, sold $602,397 | sold $6.0 million |
| Piotroski F-score | 7 of 9 | 5 of 8 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
InsuletRevvity
Operating margin
Percent of revenue
InsuletRevvity
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
InsuletRevvity